Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study (BECARES)

January 17, 2019 updated by: Haukeland University Hospital
An intervention study with longitudinal follow-up of patients with coronary artery disease undergoing early cardiac rehabilitation is designed.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The main objective of the study is to investigate patient-reported outcomes, their relation to clinical characteristics of the patients and the potential to predict health outcomes and adverse events in coronary artery disease patients participating in an early cardiac rehabilitation programme.

Study Type

Interventional

Enrollment (Anticipated)

870

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of coronary artery disease
  • >=18 years of age
  • Has performed a negative exercise test (bike or treadmill) and thereby able to participate in exercise training.

Exclusion Criteria:

  • Cognitive impairment
  • Unstable angina pectoris
  • Aortic stenosis
  • Left ventricular ejection fraction <30%
  • Heart failure NYHA class III-IV
  • Serious arrhythmia in need of treatment
  • Being on the waiting list for percutaneous coronary intervention or coronary artery bypass grafting.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Early cardiac rehabilitation
Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.

This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.

For additional analysis there will be a comparison group that did not receive the intervention for practical reasons.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to composite of total mortality, and hospitalization for heart failure and atherothrombotic disease (including non-fatal MI, unstable angina and stroke).
Time Frame: Up to 10 years
Time to combined endpoint from inclusion.
Up to 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self-reported health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The EuroQol 5-dimensions-5 level questionnaire (EQ-5D-5L) is an 5 item self-report-questionnaire assessing self-reported health. The respondent rates each item on a 5-point scale ranging from 1(indicating no problem) to 5 (indicating extreme problems). This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Change in self-reported global health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The VAS scale from the EQ-5D-5L assess global health. The scale goes from 0 to 100 were lower score indicates worse health.
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Change in post traumatic growth
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The Posttraumatic Growth Inventory-Short Form (PTGI-SF) is a 10 item scale measuring post traumatic growth. The respondent rates each item on a 6-point scale ranging from 0 (I did not experience this change as a result of my crisis) to 5 (I experienced this change to a very great degree as a result of my crisis). The scale is scored by adding all the responses.Individual factors are scored by adding responses to items on each factor. Factors are indicated by the Roman numerals after each item.
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Nicotine dependence
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The Fagerström test
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Change in anxiety and depression
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The Hospital Anxiety and Depression Scale (HADS) is a fourteen item scale where seven of the items relate to anxiety and seven relate to depression. The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). The total score is 42 (21 per subscale).
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Change in physical and mental dimensions of health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The Short Form Health Survey (SF-12) include 12 items with 3 to 5 response levels. It generates two health indices: mental health and physical health. The score range between 0 and 100, with 100 representing the highest level of health
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
Change in health status following myocardial infarction
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
The Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a PRO measure developed and validated to specifically measure the health status of individuals who have suffered a myocardial infarction. It consist of 7 domains, and is a 35 item scale where respondents rate each item on a 5-point scale ranging from 1 (never) to 5 (always). The function of the MIDAS is to indicate the extent of ill health in each of the seven domains assessed, therefore each dimension is scored separately using a simple scoring methodology.
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tone M Norekvål, PhD, Haukeland University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2013

Primary Completion (Anticipated)

February 1, 2019

Study Completion (Anticipated)

February 1, 2029

Study Registration Dates

First Submitted

December 21, 2018

First Submitted That Met QC Criteria

January 17, 2019

First Posted (Actual)

January 18, 2019

Study Record Updates

Last Update Posted (Actual)

January 18, 2019

Last Update Submitted That Met QC Criteria

January 17, 2019

Last Verified

November 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Early cardiac rehabilitation

3
Subscribe